Attending
University Hospital Heidelberg, Germany, Germany
Stefanie Zschäbitz, MD
Dept. of Medical Oncology, University Hospital Heidelberg, National Center for Tumor Diseases. Im Neuenheimer Feld 460, 69120 Heidelberg, Germany
2003-2010 Medical School at Ruprecht-Karls-University Heidelberg, Germany, Purdue University of Indiana, Indianapolis, IN, USA; University Hospital Zürich, Switzerland; Concord Repatriation Hospital, University of Sydney, Australia
02 – 07/2007 Research Scientist, Dept. of Cancer Prevention, Fred Hutchinson Cancer Research Center, Seattle, USA (Prof. Dr. sc. hum. Cornelia Ulrich)
06/2010 Licence to practice medicine in Germany
07/2010 – 04/2011 Research Scientist, Dept. Of Preventive Oncology, German Cancer Research Center Heidelberg (Prof. Dr. sc. hum. Cornelia Ulrich)
04/2011-09/2017 Residency, Dept. Of Medical Oncology, University Hospital Heidelberg (Director: Prof. Dirk Jäger, MD)
09/2017 Board Certification in Internal Medicine, Hematology, Oncology
Since 10/2017 Attending
Since 04/2019 Head of division (Sektionsleitung) „Translational Urooncology“
11/2021 Board Certification in Palliative Care
National Coordinator, Prinicipal Investigator and Subinvestigator in > 80 phase I-IV trials in the area of prostate cancer, urothelial carcinoma, renal cell carcinoma, testicular cancer, multiple entity (Basket)
Clinical focus: Genitourinary Cancers, pediatric-to-adult-transition, transplantation and cancer, training and education in oncology
Memberships AIO, ASCO, DGHO, DGIM, ESMO
SYMP-01: PARP-Inhibition + ARPI for Unselected Patients or Only HRR Mutated Patients?
Wednesday, October 29, 2025
16:30 - 16:45 GMT+0